Hyperphosphatemia

Tenapanor Monotherapy May Reduce Phosphorus Levels in Patients on Dialysis

Publish Date August 4, 2021

Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.

Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis

Publish Date July 20, 2021

Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.

In-Center Nocturnal Hemodialysis May Improve HRQOL

Publish Date June 30, 2021

In a small Canadian study, investigators found that patients switched from conventional to in-center nocturnal hemodialysis experience improvements in various measures of health-related quality of life, especially mental health.

SHPT, Hyperphosphatemia Independently Linked With CKD Progression

Publish Date June 15, 2021

Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.

Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events

Publish Date June 3, 2021

Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.

Primary Failure of Arteriovenous Fistulas Linked to Elevated Phosphorus

Publish Date May 20, 2021

Maintaining the patency of the AVF may be challenging in patients with hyperphosphatemia, study findings suggest.

Study IDs Most Effective Strategies to Reduce Fibroblast Growth Factor 23

Publish Date April 21, 2021

Circulating FGF23 starts to rise in early stage CKD before the development of other abnormalities such as high parathyroid and phosphate levels and low calcium and 1,25(OH)2D levels.

Possible Optimal Parathyroid Hormone Range in Hemodialysis Cases Identified

Publish Date April 20, 2021

Investigators found a U-shaped relationship between serum intact parathyroid hormone levels and death risk in Chinese patients initiating hemodialysis.

Tenapanor May Improve Phosphate Normalization in the Dialysis Population

Publish Date April 19, 2021

Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.

Nicotinamide May Improve Phosphate Control in Hemodialysis Patients

Publish Date March 10, 2021

Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.